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 Recent advances in pharmacogenomics have heralded 
the current era of personalized medicine – using genetic 
testing to select the best medication for patients. This 
practice has the potential to reduce the trial-and-error 
method of prescribing and side effects  [1] . However, the 
science and clinical application of genetic testing for per-
sonalized medicine have not yet caught up to the vision. 
Due to the gap between scientific advances and practical 
application the current trend of marketing specific drugs 
to different racial/ethnic groups has arisen. As a result, in 
the absence of ubiquitously available pre-prescription ge-
netic testing and genetically tailored therapies, physi-
cians may use race as a proxy for testing before treating. 
Such decisions are likely due to a commonly held belief 
that genetics and race are linked and a provider’s desire 
to personalize treatment choices. As health professionals 
continue down the road of personalized medicine, it will 
be important to understand the acceptance of these prac-
tices among diverse patients.
 In its report on the potential of pharmacogenomics 
the Advisory Committee on Genetics, Health, and Soci-
ety to the Secretary of the U.S. Department of Health and 
Human Services calls for the engagement of the lay com-
munity on issues pertaining to the benefits, risks, and 
limitations of genetic technology  [2] . These issues include 
perceptions of and receptiveness to pharmacogenomics 
and willingness to use the technology and participate in 
studies. In past research lay health consumers have ex-
pressed concerns that the cost and availability of new 
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 Abstract 
 Aims: Although recent advances in pharmacogenomics are 
making possible the use of genetic testing to determine the 
best medication for patients, little is known about how pa-
tients view such procedures. The aims for this study that 
were developed collaboratively as part of a community-aca-
demic partnership are: (1) What are the attitudes and percep-
tions of prescription drug consumers concerning personal-
ized medicine and genetic testing for drug compatibility 
and how do they differ between African American and white 
patients? (2) What are the attitudes and perceptions of pa-
tients concerning race-based prescribing and how do they 
differ between African American and white patients?  Meth-
ods: We conducted 6 focus groups, 2 with white participants 
and 4 with African American participants. Focus groups were 
audio-recorded, transcribed, and analyzed to ascertain com-
mon themes.  Results: Our results suggest that personalized 
medicine and genetic testing, though not well understood 
by lay persons, were considered positive advances in medi-
cine. However, participants also voiced concerns about these 
advances that differed by race.  Conclusion: This study points 
to the need to include perspectives of at-risk communities 
as we move toward wider use of this technology. 
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medications may result in widening health inequalities 
 [3] and that genetic testing might lead to breaches of con-
fidentiality, misuse of positive test results, and discrimi-
nation by insurers  [4] . In addition marketing messages 
linking race, genes, and heart disease that specified blacks 
or whites as the subject of the message led to higher levels 
of racist attitudes such as belief in a genetic basis for rac -
 ism  [5] .
 While some research on genetic technology has exam-
ined racial differences and included community mem-
bers’ input into the study  [6] , we have found no studies 
that have gone as far as to engage the lay community in 
posing the research questions or designing the research 
study. The present study fills that gap by being part of a 
larger project that employs community-based participa-
tory research (CBPR) strategies. In addition to its other 
benefits, community participation has been demonstrat-
ed to be an important component in overcoming mistrust 
of health researchers by marginalized populations be-
cause individuals directly affected by the research topic 
are involved in the research  [7–9] . Moreover, community 
engaged research is more likely to produce results that are 
trusted by those affected and lead to meaningful commu-
nity change. The research questions for this study that 
were developed collaboratively as part of a community-
academic partnership are: (1) What are the attitudes and 
perceptions of health care consumers concerning person-
alized medicine and genetic testing for drug compatibil-
ity and how do they differ between African American 
(AA) and white patients? (2) What are the attitudes and 
perceptions of patients concerning race-based prescribing 
and how do they differ between AA and white patients?
 Methods 
 Research Collaboration Background 
 In 2003 researchers from the University of North Carolina, 
Chapel Hill (UNC) Program on Ethnicity, Culture, and Health 
Outcomes came together with the leadership of The Partnership 
Project in collaboration to reduce health disparities. The resulting 
Health Disparities Collaborative was formed by community lead-
ers, public health researchers, clergy, and healthcare professionals 
following the 9 principles of CBPR  [10] . CBPR is an orientation to 
research that combines methods of inquiry with community ca-
pacity-building strategies in an effort to produce social change to 
improve health  [11] . The CBPR principles that we follow include 
negotiating a working process that includes team-building, pow-
er-sharing in decision making, equal partnerships, and shared 
learning. The impetus for incorporating CBPR strategies is to ad-
dress the disconnect between knowledge gained from conven-
tional research and the translation of new knowledge into actions 
that improve the health of marginalized populations. The forma-
tion of an equitable research partnership with members of such 
communities allows community members to have ownership of a 
project, collaborate on intervention implementation, and trust 
the findings.
 In 2007, as part of the UNC Clinical and Translational Science 
Award effort, researchers from UNC came to the Collaborative 
and asked members to describe the health issues of concern to 
them. One of these issues was the respectful prescribing of medi-
cations and whether prescribing behaviors differed depending on 
a patient’s race. Researchers and Collaborative members devel-
oped a workgroup that jointly developed the research questions 
and study design and conducted the study.
 Sampling Strategy and Recruitment 
 Study participants were recruited from 2 clinics and a family 
practice center at a large public medical center in a central North 
Carolina city. These clinics were selected to ensure a diverse de-
mographic mix of study participants. To be eligible, participants 
had to be between 25 and 70 years and be consistently on a medi-
cation prescribed by their regular provider. Preference was given 
to those who took medications for chronic conditions. Clinic staff 
approached patients when they came in for an appointment and 
told them about the purpose of the study and the incentive for 
participation (a $35 gift card). If a patient was interested, his/her 
contact information was relayed to the study coordinator. The 
study coordinator telephoned each participant, screened for eli-
gibility, extended an invitation to participate in a focus group, and 
gave information on the time, date, and location of the focus 
group. A signed informed consent document was obtained from 
each participant prior to the focus group.
 Data Collection 
 Focus group interviews, stratified by race, were conducted to 
ensure thematic saturation. A trained facilitator, matched by race, 
moderated each group. Between December 2007 and May 2008, 
6 focus groups were held, 2 with white and 4 with AA participants. 
Focus groups lasted approximately 90 minutes. Data were col-
lected on sociodemographics, health insurance status, and pre-
scription drug coverage of the participants. Audio recordings 
were transcribed and reviewed for accuracy. The study was ap-
proved by the medical center institutional review board.
 The moderators’ guide consisted of primarily open-ended 
questions developed by the community-academic working group. 
The guide begins with questions about considerations medical 
providers should be aware of when prescribing medication. Par-
ticipants were then asked whether medications should be pre-
scribed based on gender or race, how prescribing medication 
based on race might affect racism, and views on personalized 
medicine. The definition of personalized medicine provided to 
the participants was: ‘Personalized medicine is the management 
of a patient’s disease by understanding how an individual’s genes 
affect how his/her body responds to medications. Science is trying 
to identify and record as many genetic variations as possible. Sci-
entists can then match a person’s gene profile with the likely re-
sponse to a medication. Your unique genetic profile can help your 
doctor personalize your treatment.’  ‘For example, a 40-year old 
African American woman who has a high chance of developing 
breast cancer based upon a defect in a certain gene that she carries 
can work with her doctor to determine if she is among a percent-
age of those for whom a particular drug is likely to work.’
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 Other topics covered included views on genetic testing for 
drug compatibility, reasons for non-adherence to prescription 
medication, and experiences with pharmacists.
 Analytic Strategy 
 The workgroup conducted an initial review of the transcripts 
to look for new or emergent themes. Next, potential themes and 
subthemes were developed based on the literature review, re-
search questions, and focus group questions. Workgroup mem-
bers met to discuss initial impressions. A codebook was created 
with definitions for themes and subthemes and rules for coding 
the text data. One workgroup member coded all 6 transcripts, us-
ing ATLAS.ti (ATLAS.ti, Berlin, Germany), based on discussion 
by the full group.
 The number of text pieces sorted into each code was reviewed 
to ascertain relative magnitude and to look for patterns with the 
rule that patterns must be supported by at least 3 occurrences of 
the same idea  [12] . Themes were examined with the focus group 
being the unit of analysis. Group members met to interpret the 
results.
 Results 
 A total of 48 people participated in the 6 focus groups 
(34 AA [70.83%], 14 white [29.17%]). Of the 6 groups, 4 
were conducted with predominately low SES (socioeco-
nomic status) AAs, 1 with low SES whites, and 1 with 
higher SES whites. The demographic and insurance char-
acteristics of each focus group are shown in  table 1 . Char-
acteristics of the participants include that 79.41% of the 
AA participants were female and 26.47% were married 
and 71.43% of the white participants were female and 
78.57% were married.
 Focus group participants were asked their opinions of 
the practices of personalized medicine, race-based pre-
scribing, and genetic testing. These opinions and the dif-
ferences between AA and white focus groups are de-
scribed below. Illustrative quotes are shown in  table 2 .
 Attitudes towards Personalized Medicine 
 All focus groups held generally positive views of per-
sonalized medicine. However, participants in the AA 
 focus groups spent a greater amount of time discussing 
positive views than did the white focus groups. These 
positive aspects included fewer side effects and less trial-
and-error when prescribing. In contrast, white focus 
groups concentrated more on the view that while person-
alized medicine is an exciting prospect it will take time 
before the full potential is realized.
 AA focus groups were concerned about the cost of per-
sonalized medicine and what that would mean for those 
with a limited ability to pay because they lack insurance 
that will cover it or do not have the money to pay for the 
procedure out-of-pocket. Finally, there was much agree-
ment in one AA focus group that even with personalized 
medicine medical mistrust would still be an issue. These 
themes were absent from the white focus groups.
 Attitudes towards Genetic Testing 
 Participants had much less to say about genetic testing 
than personalized medicine, in part due to limited knowl-
edge about genetic testing and the need for pre-prescrip-
tion testing. In fact, participants in both white focus 
groups and 1 of the AA focus groups expressed a desire 
to know more about the practice before they would par-
ticipate. Still, similar to personalized medicine, both AA 
and white groups held similarly favorable views of genet-
ic testing as a way to find the best medication. Both groups 
Table 1. Focus group demographics
Group Race n Age 
range
Female Married High school diplo-






1 AA 11 27–61 7 (63.6%) 4 (36.4%) 8 (72.7%) 7 (63.6%) 9 (81.8%)
2 white 9 38–63 7 (77.7%) 6 (66.7%) 5 (55.6%) 1 (11.1%) 3 (33.3%)
3 AA 8 41–70 6 (75.0%) 4 (50.0%) 8 (100%) 1 (12.5%) 2 (25.0%)
4 white 5 54–64 3 (60.0%) 5 (100%) 5 (100%) 2 (40.0%) 2 (40.0%)
5 AA 7 35–53 6 (85.7%) 0 6 (85.7%) 0 4 (57.1%)
6 AA 8 34–65 8 (100%) 1 (12.5%) 6 (75.0%) 0 1 (12.5%)
Total 48 27–70 37 (77.1%) 20 (41.7%) 38 (79.2%) 11 (22.9%) 21 (43.8%)
a Many participants were on Medicaid or Medicare with only minimal prescription drug coverage.
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Table 2. Thematic quotations on positive and negative aspects of personalized medicine, race-based prescribing, and genetic testing 
from African American (AA) and white focus groups
AA White
Personalized medicine
Positive ‘Like you say with joint problems, stomach upset, the medicine may be able to more synthesize with your 
system so that you’re not experiencing all of these different emotional ups and downs, um, sickness, diar-
rhea, constipation … all the other symptoms, all the other side effects.’ (FG5)
+
‘And, it’s not as time consuming as it is if you keep going back and forth to the doctor trying to figure out 
what’s gonna work.’ (FG6)
+
Negative ‘I think our knowledge base is so minimal on this right now too. It’s gonna be a very long time til this is 
 gonna be any kind of trustworthy even component of the whole prescription process. I mean, you think 
about medication interactions. When you’re testing efficacy and safety of drugs and, and doing it on the 
 basis of genetic profile, you can’t test every combination of all the thousands of drugs that are out there.’ (FG2)
+
‘M: Can you see any disadvantages?
R: To me just the cost like she said.
R: I think it gonna depend on, again, public or private insurance.
M: If insurance covers it?
R: Mmm, insurance, yeah.’ (FG5)
+
‘I think there would still be a trust issue though with the medical community. I think that’s the, that’s the 
problem that we get into when we start talking about personalized medicine.’ (FG5)
+
Genetic testing
Positive ‘Because that way they’ll know that will work for me and what won’t work for me, and … it won’t take me 
through the, you know, uh, thing of getting this prescription, trying this, you done spent your money on 
this, this doesn’t work. You don’t get a refund.’ (FG1)
+ +
‘It will save you some other conditions too … Save you going through the, the sickness or sometimes you’ll 
be sick for 2 weeks while taking a pill.’ (FG5)
+ +
Negative ‘I think that’s a win-win for everybody, but probably so cost prohibitive that couldn’t even be done in the 
near future, on any regular basis. But, sounds good.’ (FG4)
+
‘But, even if … you have private healthcare insurance … and the doctor wants to do this genetic testing
to see whether that works best for you or not. The health insurance company may decide that it’s not
necessary, and it’s too expensive, and they want to do the old trial-and-error way.’ (FG2)
+
‘R1: Your insurance company gets a hold of it [genetic information], well, what’s gonna happen to your 
 premiums?
R3: Well, they’re gonna drop you, or, they’re, or …
R3: Your premiums are gonna go sky high.
R1: Or your perspective employer. They don’t want to hire you if they know your gonna get sick.’ (FG2)
+
‘I would be interested in, in genetic testing. But, it’s, it’s something you don’t enter into lightly. I mean I’m 
not sure how I would feel if somebody tells me you have the BRCA gene or whatever it is for breast cancer.
I don’t know right now if I want to know that.’ (FG2)
+
Race-based prescribing
Positive ‘Some medications have been researched to say they fit one ethnicity better than another.’ (FG3) +
‘I actually think it’s a good idea because genetically the races are different, I mean look, you just have to
look at the preponderance of African Americans with hypertension.’ (FG2)
+
‘So, we’re gonna tell a whole group of people, “I’m sorry, you gotta take this medication because this is
socially acceptable”?’ (FG4)
+
Negative ‘Because so much has been, been given to … us in particularly our, our community, black people, that …
there’s a big factor of whether or not they’re giving us stuff to help us or to hurt us.’ (FG5)
+
‘The ones that’s on Medicare or Medicaid or no insurance at all they should be able to get the same thing, 
[as] those that can afford to get their medicine. Because see … when a doctor takes an oath … to help that 
person no matter, no matter the race, how much money you got, or anything, they’re not supposed to look 
at those things.’ (FG6)
+ +
‘Because that’s racist to say like she white, I’m black, we both got diabetes but her, her diabetes is a lot
worse than mine. Uh, but, but he gonna give me the … stuff that’s gonna hurt me, but gonna give her the 
stuff that’s gonna help bring down her, uh, sugar level. Nope. That ain’t right.’ (FG6)
+ +
‘I think they should treat them just like they treat me, or her, or any of us.’ (FG4) + +
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saw genetic testing as a promising practice for reducing 
the risks in the current method of prescribing. Similar to 
the views of personalized medicine, participants believed 
that genetic testing would decrease side effects and re-
duce the trial-and-error nature of prescribing, thus sav-
ing money.
 White focus group participants talked to a greater ex-
tent about genetic testing than did AA groups. The white 
focus groups held positive views on genetic testing but 
expressed concern that the practice would be too expen-
sive to be accessible. White focus group members also 
agreed that insurance companies might not pay for a pro-
cedure to determine the best medication because of high 
costs. In addition, white groups, confounding genetic 
testing to determine drug compatibility and genetic test-
ing to assess disease vulnerability, worried about possible 
insurance and employment discrimination due to dis-
covery of a genetic predisposition for a specific disease or 
from simply being tested. White groups also expressed 
concerns about receiving clinically important informa-
tion. There was agreement in the white groups that they 
would not want to know if they had a genetic predisposi-
tion for some diseases and that genetic testing should be 
entered into with a degree of caution.
 As opposed to the discussion in the white groups, 
there was only 1 mention of a negative aspect of genetic 
testing in any of the AA focus groups. This participant 
believed that she was already taking too many medica-
tions and genetic testing would just increase the number 
she had to take.
 Attitudes towards Race-Based Prescribing 
 White and AA focus groups held some similar and 
some disparate views of race-based prescribing. There 
was minimal discussion in the AA focus groups regard-
ing positive aspects of race-based prescribing. One AA 
participant had heard of medications that were race-spe-
cific, perhaps referring to BiDil, the first medication ap-
proved specifically for AAs  [13] . One participant in an 
AA focus group thought that prescribing medications 
based on race made sense, but there was no agreement 
with this in the focus group. The majority of the discus-
sion in AA focus groups around race-based prescribing 
revealed negative views, including strong endorsement of 
medical mistrust. AA focus group participants strongly 
endorsed the sentiment that race-based prescribing was 
racist and AAs might receive inferior medications be-
cause of this practice.
 Contrary to what was seen in the AA focus groups, 
white focus groups did hold some positive views of race-
based prescribing. White focus groups reasoned that be-
cause certain groups of people are prone to particular ill-
nesses race-based prescribing may be a good option. Oth-
er white focus groups cited concerns such as people with 
lighter skin being more susceptible to skin cancer and 
Asian individuals having reactions to alcohol as support-
ive of race-based therapies. Still, white focus group par-
ticipants disagreed about whether medications should be 
prescribed based on race. Some white focus group mem-
bers were worried about issues of equity. However, one 
white participant voiced, and others agreed, that in an ef-
fort to treat everyone the same, we might miss out on 
more effective treatment options.
 White focus groups worried that race-based prescrib-
ing might cause insurance premiums to rise for certain 
races if they were found to be more susceptible to certain 
diseases. They also worried that individuals with public 
insurance or none at all would receive inferior care. There 
was strong agreement in one white group regarding this 
idea. White participants also noted that while race may 
be useful for tailoring medications the practice could per-
petuate discrimination.
 Of note, both AA and white focus groups conflated 
race with socioeconomic class when discussing their at-
titudes about race-based prescribing, although for AA 
 focus groups this was more pronounced. Two AA focus 
groups expressed concerns about receiving the best med-
ications regardless of insurance status and stated that 
race should not be a factor.
 Returning Results to the Community 
 The workgroup felt the results should be shared with 
the community to provoke transformative action on per-
sonalized medicine and the issues of the larger study. This 
sharing of results to create change is a key aspect of CBPR 
 [11] . Toward that end, a community forum was held to 
share findings and provide study participants with infor-
mation to address their concerns and some misunder-
standings about prescribing practices and personalized 
medicine. Community members of the workgroup took 
responsibility for preparing and presenting the majority 
of the information during the forum. Focus group par-
ticipants, many of whom had expressed reticence toward 
participation in research or genetic testing to determine 
drug compatibility, were given the opportunity to learn 
more about participation in a clinical trial and its benefits. 
Participants were given information on the importance of 
knowing their family medical history and how to collect 
that information as a way of receiving more appropriate 
care until genetic testing is widely available.
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 In addition to the forum, study findings were carried 
in the regional newspaper and shared through the quar-
terly in-house publication for health care providers and 
staff from the health care system where the participants 
received their care. Next steps in addressing the findings 
include providing training to physicians within the local 
health care system using the Partnership Project’s ‘Undo-
ing Racism’ curriculum as a basis for better communica-
tion with patients. Another effort under consideration 
will be to conduct roundtable discussions with focus group 
participants to identify workable solutions that improve 
patient-provider communication around these issues.
 Discussion 
 In this study, we examined patients’ attitudes about 
personalized medicine, genetic testing, and race-based 
prescribing and whether they differed between white and 
African American participants. Our results suggest that 
personalized medicine and genetic testing, though not 
well understood by lay persons, were considered positive 
advances in medicine. However, participants also voiced 
a range of concerns. For example, participants felt that, 
while promising, the use of genetic testing to personalize 
medicine might be too expensive to be accessible to the 
general public. We also found that medical mistrust by 
marginalized populations, as discussed in particular in 
the AA focus groups, may affect the acceptability of per-
sonalized medicine when it becomes widely available. 
Further, our results contribute to the field by demonstrat-
ing that lay persons are suspicious of the practice of using 
race as a method for tailoring medications, a finding 
more pronounced in AA participants than whites and 
made particularly relevant by the BiDil study  [13] . Still, 
African Americans viewed personalized medicine and 
genetic testing as positive developments that could re-
duce the trial-and-error nature of prescribing and the 
possibility of side effects. It is encouraging that African 
Americans hold these views because it suggests that they 
may accept this new technology, which is particularly im-
portant in light of previous research  [14, 15] indicating 
that African Americans may potentially derive greater 
benefit from such technology than whites.
 Beyond  the findings themselves, the importance of 
the methods utilized cannot be overlooked. The CBPR 
framework allowed for community involvement in a rich 
discussion of complex issues that identified barriers and 
perceptions that an investigator-centric approach could 
not have developed. This is one of the few studies con-
cerning genetics and genetic research that has actively 
engaged community members in the research process 
from development of research questions to study design 
and data analysis. Another study engaged the commu-
nity by asking lay persons to provide feedback on consent 
forms for use when collecting blood samples  [16] . How-
ever, community members were not involved in the study 
design, data collection, analysis, and dissemination of re-
sults as in the present study.
 The current status of personalized medicine and race-
based prescribing has been well documented in the scien-
tific literature  [17, 18] . However, this academic-commu-
nity partnership provides a process not only to identify 
how lay persons feel about complex genetic topics but also 
provides a vehicle for addressing the issues that arise. In 
addition, by involving lay persons as equal partners in 
research, the community takes ownership for the find-
ings and their dissemination. The engagement of com-
munity in conducting research, disseminating findings, 
and educating the public could be particularly powerful 
in reducing barriers to the use of personalized medicine 
by making complex topics relevant and understandable 
and helping researchers recognize the concerns and needs 
of communities.
 Overall, study participants, regardless of race, deemed 
personalized medicine and genetic testing to be benefi-
cial; however, many of them did not have a clear under-
standing of what these practices entail. Clearly as pre-
prescription genetic testing and personalized medicine 
become more widespread, improving lay literacy on the 
terms and procedures involved will be critical to accep-
tance of research and clinical application. In particular, 
patients need to understand the purpose of genetic test-
ing and how it can be used together with other clinical 
information to determine the best treatment. Health pro-
fessionals will need to draw from many disciplines such 
as psychology, anthropology, and advertising to create 
social marketing campaigns that address the numerous 
barriers to acceptance and utilization.
 Even in the face of overall positive views of personal-
ized medicine, some participants were wary of participat-
ing in any sort of medical testing, believing that they might 
be exploited or the privacy of test results be compromised. 
One way to address this concern is to provide patients with 
information about the Genetic Information Nondiscrimi-
nation Act (GINA), legislation signed into law in 2008 to 
protect patients from discrimination by their health insur-
ers and employers based on their genetic information. An 
approach similar to the dissemination of information dur-
ing health care visits on the Health Insurance Portability 
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and Accountability Act (HIPAA), which set national stan-
dards for the protection of the privacy of personal health 
information, could be undertaken. Dissemination of in-
formation on GINA may address concerns about the leak-
age of test results, but worry about potential exploitation 
may still exist. As seen in this study, community involve-
ment can be vital to addressing these concerns. Academic-
community partnerships can help address mistrust of the 
medical community by historically marginalized people 
through facilitated dialogue between members of these 
groups and the medical community. In addition, medical 
providers, public health professionals, and health re-
searchers can address key misperceptions about genetic 
testing, for example patient concerns that genetic testing 
is an experiment which will not give direct benefit.
 The results of this study can also be used to educate 
genetic scientists and medical providers about patients’ 
attitudes concerning personalized medicine and genetic 
testing. If scientists developing genetic tests and targeted 
medications and medical providers prescribing them un-
derstand these misperceptions and reservations, the con-
cerns can be addressed using appropriate marketing in-
formation and direct conversation with patients in the 
office setting.
 The results of this study should be viewed in light of 
its limitations. One limitation is that 1 of the 2 white focus 
groups was held with higher SES participants, while all 
AA focus groups were held with predominantly low SES 
participants. Differences seen between the 2 racial groups 
may be attributable to class not race; however, the groups 
represent the demographic mix seen in the healthcare 
system and local community from which they were re-
cruited. Also, focus groups are subject to the dynamics of 
the group, which may be dominated by a small number 
of voices. Future research may benefit by utilizing an-
other method of data collection that allows anonymity, 
such as a survey, which may elicit divergent views that 
people may be uncomfortable voicing within a group. 
Last, participants confused genetic testing to assess dis-
ease vulnerability with testing to determine the most ap-
propriate medication due to the complexity of these tech-
nologies, even though, to combat this, we were careful to 
probe for opinions to specific technologies. Future re-
search may benefit from the provision of even more ex-
amples of the differences between these 2 technologies to 
anchor participant discussion.
 When asked their opinions about personalized medi-
cine, genetic testing, and race-based prescribing, African 
American participants appeared to be most concerned 
about the receipt of inferior medications and expressed 
general mistrust of the motives of the medical commu-
nity while white participants were concerned about cost. 
Both groups were concerned about what these practices 
would mean in terms of equity, but African American 
participants were concerned about this for themselves 
while white participants were thinking of society at large. 
This difference is understandable in light of the historic 
exploitation perpetrated on the African American com-
munity  [19] . Another difference was that fewer African 
Americans than whites in this sample had prescription 
drug coverage, which may explain the finding that Afri-
can Americans were concerned that these new technolo-
gies would cost more than they could afford to pay out-
of-pocket while whites worried that the high cost meant 
that insurance companies would not cover medications 
prescribed via this method. Despite these misgivings, 
both African American and white participants believed 
that personalized medicine was a good idea, although one 
with which they were not yet familiar. As the state of the 
science of genetic testing for drug compatibility marches 
forward, we must not lose sight of the patients’ perspec-
tive. Personalized medicine will not reach its potential 
without concerted and effective efforts to involve and ed-
ucate at-risk communities.
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